Matthew Seymour, MD: A Clinical Trialist’s Perspective

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Opportunities to Optimize Cancer Policies Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Feb

Today In Oncology

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Related Videos

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Opportunities to Optimize Cancer Policies Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

A Paradigm Shift In Treating Adult AML?

Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says

VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer

Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans

FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency